Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best upside stocks to buy now.
Apellis Pharmaceuticals Inc. (APLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 12,222,222 | $276,588,884 | 3.58% | |
| 2. | Deep Track Capital David Kroin | 8,000,382 | $181,048,645 | +15% | 5.05% |
| 3. | AQR Capital Management Cliff Asness | 4,487,354 | $101,548,820 | -25% | 0.07% |
| 4. | EcoR1 Capital Oleg Nodelman | 3,447,156 | $78,009,140 | -72% | 3.74% |
| 5. | Suvretta Capital Management Aaron Cowen | 2,878,000 | $65,129,140 | 1.67% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 250,000 | $10,000,000.00 | 12,806,342 | 2021-11-18 | Filing | |
| $31.81 | 5,000 | $159,034.00 | 5,000 | 2020-05-08 | Filing | |
| $37.00 | 540,540 | $19,999,980.00 | 12,556,342 | 2020-01-13 | Filing | |
| $29.71 | 11,699 | $347,629.94 | 11,699 | 2019-08-29 | Filing | |
| $17.00 | 441,176 | $7,499,992.00 | 12,015,802 | 2019-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.06 | 5,000 | $100,300.00 | 108,730 | 2025-11-17 | Filing | |
| $28.03 | 10,000 | $280,300.00 | 110,936 | 2025-10-21 | Filing | |
| $25.22 | 5,000 | $126,100.00 | 113,730 | 2025-10-16 | Filing | |
| $23.72 | 31,092 | $737,536.44 | 3,837 | 2025-10-10 | Filing | |
| $22.58 | 31,092 | $702,057.36 | 33,979 | 2025-09-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,987,394 | $226,014,726 | 0% | |
| 2. | 9,643,248 | $218,226,717 | 0.01% | |
| 3. | 9,290,960 | $210,254,425 | 0.04% | |
| 4. | 6,268,465 | $141,855,364 | 0% | |
| 5. | 4,348,055 | $98,396,482 | 0.06% |
News See All
12 Best Upside Stocks to Buy Now
On November 14, Alli McCartney, UBS Private Wealth Management managing director, joined 'Squawk Box' on CNBC to discuss the latest market trends and what to make of the recent volatility.
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) ranks among the most oversold biotech stocks to invest in. On November 3, Mizuho maintained its Neutral rating for Apellis Pharmaceuticals Inc.
9 Oversold Biotech Stocks to Invest In
Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and healthcare.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals Third Quarter 2025 Earnings Conference Call.
12 Oversold Growth Stocks to Buy According to Analysts
On September 27, Wharton professor emeritus and WisdomTree senior economist Jeremy Siegel joined CNBC for an interview to discuss the latest PCE report and what the data reveal about the market.
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), headquartered in Massachusetts, is a global biopharmaceutical enterprise advancing treatments for diseases through complement system modulation.
11 Best Short-Term Stocks to Invest in
The latter half of the 2025 market is caught between conflicting signals.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Second Quarter 2025 Apellis Pharmaceuticals, Inc. Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target
In a market note on Wednesday, Scotiabank increased its price target for Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) stock to $22 from $20 previously, and maintained a “sector perform” rating...
Hedge Fund Resource Center Billionaire Hedge Funds
